Recursion Pharmaceuticals (RXRX) Net Margin (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Net Margin came in at 1815.57% in Q1 2026, down 44232.0% YoY from N/an in Q1 2025, and down 496.75% on a QoQ basis from 304.24% in Q4 2025.
Recursion Pharmaceuticals (RXRX) Net Margin (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Net Margin data on file, last reported at 1815.57% in Q1 2026.
- Quarterly Net Margin fell 44232.0% year-over-year to 1815.57% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 842.93% (up 11839.0% YoY) and the FY2025 annual result came in at 863.35%, down 7533.0% from the prior year.
- Net Margin fell to 1815.57% in Q1 2026, from 304.24% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 304.24% in Q4 2025 to a low of 3935.46% in Q4 2024.
- A 5-year average of 1118.95% and a median of 853.88% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2024 — Net Margin slumped 308158 bps — and 2025, when it jumped 363122 bps.
- Tracing RXRX's Net Margin over 5 years: stood at 497.59% in 2022, then tumbled by 72 bps to 853.88% in 2023, then tumbled by 361 bps to 3935.46% in 2024, then jumped by 92 bps to 304.24% in 2025, then slumped by 497 bps to 1815.57% in 2026.
- The last three Net Margin figures came in at 1815.57% (Q1 2026), 304.24% (Q4 2025), and 3135.32% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | -1,708.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,708.02% |
| Mar 31, 2026 | -1,815.57% |
| Dec 31, 2025 | -304.24% |
| Sep 30, 2025 | -3,135.32% |
| Jun 30, 2025 | -894.23% |
| Mar 31, 2025 | -1,373.26% |
| Dec 31, 2024 | -3,935.46% |
| Sep 30, 2024 | -367.46% |
| Jun 30, 2024 | -676.56% |
| Mar 31, 2024 | -662.41% |
| Dec 31, 2023 | -853.88% |
| Sep 30, 2023 | -883.10% |
| Jun 30, 2023 | -696.43% |
| Mar 31, 2023 | -538.38% |
| Dec 31, 2022 | -497.59% |
| Sep 30, 2022 | -475.58% |
| Jun 30, 2022 | -862.72% |
| Mar 31, 2022 | -1,049.97% |
| Dec 31, 2021 | -2,565.14% |
| Sep 30, 2021 | -1,839.86% |